A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
| العنوان: | A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma |
|---|---|
| المؤلفون: | Colin D. Weekes, Julie Huang, Erkut Borazanci, Michael J. Pishvaian, John Nemunaitis, Nishanthan Rajakumaraswamy |
| المصدر: | Oncologist |
| بيانات النشر: | Oxford University Press (OUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, endocrine system diseases, medicine.medical_treatment, Adenocarcinoma, Phosphatidylinositol 3-Kinases, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Maculopapular rash, Humans, 030212 general & internal medicine, Colitis, Adverse effect, Aged, Quinazolinones, Chemotherapy, business.industry, Clinical Trial Results, Middle Aged, medicine.disease, Pancreatic Neoplasms, Diarrhea, Purines, 030220 oncology & carcinogenesis, Pharmacodynamics, Female, medicine.symptom, business, Idelalisib |
| الوصف: | Trial Information Lessons Learned Although this study of idelalisib in patients with PDAC was limited in size and duration because of early termination, idelalisib exposure resulted in an overall safety profile consistent with studies in hematological malignancies, except that the incidences of diarrhea and colitis were reduced in patients with PDAC. Preclinical studies of the PI3K pathway in PDAC and positive clinical results of PI3K inhibition in other cancers support the continued development of PI3K inhibitors in PDAC. Background Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal solid tumors and is often refractory to treatment. Phosphatidylinositol-3 kinase (PI3K) δ inhibition influences regulatory immune cell function and improves survival in preclinical PDAC models. Here, idelalisib, an inhibitor of PI3Kδ, was investigated as treatment for metastatic PDAC. Methods This was an open-label, multicenter, phase Ib, nonrandomized, dose-escalation study. Study aims were to investigate the maximum tolerated dose, safety, pharmacokinetics/pharmacodynamics, and efficacy of idelalisib alone and in combination with chemotherapeutics—nab-paclitaxel and modified (m)FOLFOX6. Results Because of early termination, only 16 patients were enrolled in the single-agent idelalisib arm, 12 of whom received at least one dose of idelalisib. The most common treatment-emergent adverse events (≥25%) related to idelalisib (n = 12) were increased aspartate aminotransferase, pyrexia, and maculopapular rash. One patient presented with diarrhea; no cases of colitis were reported. One patient discontinued treatment because of pyrexia and maculopapular rash; two patients died because of disease progression. Conclusion This study was terminated because factors contributing to safety concerns in phase III studies of idelalisib for hematological malignancies were not fully understood. In this small sample of patients with metastatic PDAC, exposure to idelalisib resulted in safety findings consistent with previous studies, with reduced diarrhea/colitis. |
| تدمد: | 1549-490X 1083-7159 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c4435afb8148583c262a9e30fb85605Test https://doi.org/10.1634/theoncologist.2020-0321Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2c4435afb8148583c262a9e30fb85605 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1549490X 10837159 |
|---|